{
  "pmcid": "12492532",
  "sha256": "2b49b3571b75548f97a55c7a3ce19af4ec789ced601ddecc554fac3108eebcf1",
  "timestamp_utc": "2025-11-09T23:41:39.611034+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.996176470588239,
    "reading_ease": 29.24196078431376,
    "word_count": 272
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial of CYP2C19 Metabolizer Phenotype and POAF Incidence after OPCABG"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at Sichuan Provincial People’s Hospital, this retrospective cohort study included 320 patients undergoing elective first-time OPCABG from May 2017 to November 2023."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were categorized into normal metabolizer (NM), intermediate metabolizer (IM), and poor metabolizer (PM) groups based on CYP2C19 genotyping."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of POAF within the first week post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Conducted at Sichuan Provincial People’s Hospital, this retrospective cohort study included 320 patients undergoing elective first-time OPCABG from May 2017 to November 2023."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "POAF incidence was 20.9% in the NM group, 35.7% in the IM group (HR 1.843, 95% CI 1.155 to 2.940; P = 0.0076), and 57.8% in the PM group (HR 3.363, 95% CI 1.753 to 6.499; P < 0.0001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding sources were not disclosed."
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}